Cerus Corporation
NASDAQ:CERSMedical - Devices
+$0.08 today
- Market cap
- $383.71M
- Beta
- 1.77
- P/E (TTM)
- -53.8
- EPS (TTM)
- -$0.05
Volume 6.69M
Average 2.33M
Returns on capital
Cerus Corporation management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-24.3%
avg -75.9%
ROIC
-21.7%
avg -39.3%
ROA
-7.0%
avg -31.5%
Analysis
ROA is currently the strongest return metric at -7.0% versus its period average of -31.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
William Greenman | Executive Chairman of the Board | USD 1.55M | 59 | — | — |
Vivek K. Jayaraman | President, Chief Executive Officer & Director | USD 964.15K | 51 | 2.23M | 1.11% |
Kevin D. Green | Vice President of Finance & Chief Financial Officer | USD 831.57K | 54 | — | — |
Richard J. Benjamin | Chief Medical Officer | USD 792.71K | 66 | 777.36K | 0.39% |
Chrystal Jensen | Chief Legal Officer, General Counsel & Secretary | USD 755.5K | 55 | 936.66K | 0.47% |
Christian Boutemy | VP & MD of Cerus International | — | — | — | — |
Bianca Vos | Vice President of Administration | — | — | — | — |
Lainie Corten | Vice President of Corporate Strategy, Planning & Communications | — | — | — | — |
Timothy J. Lee | Head of Investor Relation | — | — | — | — |
Nina Mufti | Senior Vice President of Research & Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
23
$3.21M
Net Transaction Value
−$3.21M
Net selling
Most Active
Jayaraman Vivek K
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 17, 26Aug 17, 2026 | Jensen Chrystal Direct | Sell | $89.5K$89,529.00 |
| Jul 16, 26Jul 16, 2026 | Jayaraman Vivek K Direct | Sell | $52.7K$52,664.56 |
| Jun 30, 26Jun 30, 2026 | Jayaraman Vivek K Direct | Sell | $124.7K$124,658.30 |
| Jun 30, 26Jun 30, 2026 | Jensen Chrystal Direct | Sell | $71.6K$71,597.81 |
| Jun 30, 26Jun 30, 2026 | Greenman William Mariner Direct | Sell | $299.9K$299,937.43 |
| Jun 30, 26Jun 30, 2026 | Green Kevin Dennis Direct | Sell | $99.1K$99,105.10 |
| Jun 9, 26Jun 9, 2026 | BJERKHOLT ERIC Direct | Sell | $53.2K$53,180.40 |
| May 29, 26May 29, 2026 | Jayaraman Vivek K Direct | Sell | $50K$50,001.00 |
| May 1, 26May 1, 2026 | Jayaraman Vivek K Direct | Sell | $50K$50,001.00 |
| Mar 12, 26Mar 12, 2026 | Jayaraman Vivek K Direct | Sell | $273.8K$273,769.44 |
1–10 of 23
Summary
Insiders reported 0 buys worth $0.00 and 23 sells worth $3.21M over the last 12 months. That adds up to net selling of $3.21M. Jayaraman Vivek K was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +8.4% | +12.2% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Recent growth has been strongest in Revenue at +8.4% over three years. Forward estimates point to Revenue at +12.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Cerus Corporation compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CERS's management, answered from reported figures.
Who manages CERS?
Cerus Corporation (CERS) lists 10 active executives. The top listed executive is Richard J. Benjamin, Chief Medical Officer.
Are CERS insiders buying or selling?
Recent insider activity shows net selling of $3.05M.
Continue the stock analysis
Jump to another research area for this company.